Lord, Abbett & Co
PCRX icon

Lord, Abbett & Co’s Pacira BioSciences PCRX Stock Holding History

Lord, Abbett & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-569,913
Closed -$43.8M – 926
2015
Q4 		$43.8M Buy
+569,913
New +$32.3M 0.13% 240
2015
Q1 		– Sell
-208,738
Closed -$18.5M – 940
2014
Q4 		$18.5M Sell
208,738
-170,314
-45% -$16.1M 0.05% 487
2014
Q3 		$36.7M Buy
+379,052
New +$36.9M 0.09% 308

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Lord, Abbett & Co's PCRX Position: Q1 2016 in Review

Lord, Abbett & Co sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 569,913 shares — an estimated $43.8M sold.

Lord, Abbett & Co first reported a position in PCRX in Q3 2014 and held it in 3 quarters. The position peaked at $43.8M in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

  • Lord, Abbett & Co reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
  • Lord, Abbett & Co sold 569,913 Pacira BioSciences shares in Q1 2016, an estimated $43.8M.
  • Lord, Abbett & Co first reported a position in Pacira BioSciences in Q3 2014 and held it in 3 quarters.
  • Lord, Abbett & Co's Pacira BioSciences position peaked at $43.8M in Q4 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Lord, Abbett & Co's 13F filing for Q1 2016, filed 16 May 2016.